These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20592626)

  • 1. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website.
    Subramanian J; Madadi AR; Dandona M; Williams K; Morgensztern D; Govindan R
    J Thorac Oncol; 2010 Aug; 5(8):1116-9. PubMed ID: 20592626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site.
    Subramanian J; Regenbogen T; Nagaraj G; Lane A; Devarakonda S; Zhou G; Govindan R
    J Thorac Oncol; 2013 Jul; 8(7):860-5. PubMed ID: 23478543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
    Gentzler RD; Yentz SE; Johnson ML; Rademaker AW; Patel JD
    Cancer; 2014 Dec; 120(24):3853-8. PubMed ID: 25155290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry.
    McCoach CE; Berge EM; Lu X; Barón AE; Camidge DR
    J Thorac Oncol; 2016 Mar; 11(3):407-13. PubMed ID: 26725180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emepepimut-S for non-small cell lung cancer.
    Corrales-Rodriguez L; Blais N; Soulières D
    Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
    Ghimire S; Kyung E; Kim E
    Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
    Harper P
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer.
    Freidlin B; Breathnach OS; Johnson BE
    Clin Cancer Res; 2003 Mar; 9(3):917-22. PubMed ID: 12631588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping.
    Sacher AG; Le LW; Leighl NB
    J Clin Oncol; 2014 May; 32(14):1407-11. PubMed ID: 24590634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions.
    Bunn PA
    Semin Oncol; 1994 Jun; 21(3 Suppl 6):49-59. PubMed ID: 8052874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
    Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB
    J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
    Yang YJ; Park JC; Kim HK; Kang JH; Park SY
    Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?
    Sacher AG; Le LW; Leighl NB; Coate LE
    J Thorac Oncol; 2013 Mar; 8(3):366-8. PubMed ID: 23407560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current readings: Window-of-opportunity trials for thoracic malignancies.
    Tsao AS
    Semin Thorac Cardiovasc Surg; 2014; 26(4):323-30. PubMed ID: 25837547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
    Koch A; Bergman B; Holmberg E; Sederholm C; Ek L; Kosieradzki J; Lamberg K; Thaning L; Ydreborg SO; Sörenson S;
    Eur J Cancer; 2011 Jul; 47(10):1546-55. PubMed ID: 21565487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
    De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
    J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.
    Mauri D; Pentheroudakis G; Bafaloukos D; Pectasides D; Samantas E; Efstathiou E; Kalofonos HP; Syrigos K; Klouvas G; Papakostas P; Kosmidis P; Fountzilas G; Pavlidis N;
    Anticancer Res; 2006; 26(4B):3175-81. PubMed ID: 16886653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.